infections were caused by Enterococcus faecalis. In the last few years, Enterococcus faecium have evolved as a common nosocomial pathogen and partially replaced E. faecalis as a cause of hospital-associated infections [3] [4] . This change is related to the fact that E. faecium has a number of mechanisms of intrinsic resistance and is also able to acquire resistance by mutations or incorporation of genes located on plasmids, transpozons, or integrons [3] . The largest threats are strains resistant to glycopeptides (VRE -vancomycin-resistant Enterococcus) [1, 5] .
During the past 15 years the knowledge about genetic background and molecular mechanisms responsible for glycopeptide resistance has been increasing [5] [6] . Enterococcus resistant to glycopeptides produce cell-wall precursors with decreased affi nity for the drug, which prevents the antibiotic from blocking cell-wall synthesis [7] . Nowadays, there are ten known types of enterococcal resistance to glycopeptides: VanA, VanB, VanC, VanD, VanE, VanF, VanG, VanL, . VanA and VanB types occur most frequently; VanA is responsible for a high level of resistance to both vancomycin and teicoplanin, whereas VanB confers only a low level of resistance to vancomycin while susceptibility to teicoplanin is conserved. Other types are rarely found in Enterococcus species [10] . van genes are most often located on transpozons (e.g., vanA on Tn1546, vanB on Tn1549/Tn5382) or on plasmids, and they transfer between enterococcal isolates by plasmid conjugation or transposition [5, 7] .
In the treatment of enterococcal infections, the use of a cell-wall active agent (ß-lactam, glycopeptide) with an aminoglycoside results in synergistic antibacterial activity [11] . E. faecium has high-level resistance to many β-lactams as a consequence of modifi cation of penicillin-binding proteins (PBP), or very rarely, by the production of a β-lactamase enzyme [15] . High-level aminoglycoside resistance (HLAR), caused by production of aminoglycoside-modifying enzymes (AMEs), makes therapy with aminoglycosides and ß-lactams ineffective [11] . At present, over 70 such enzymes have been discovered; their genes are also located on mobile genetic elements and are widespread among Enterococcus [11] [12] . Two of the most prevalent AME genes, aac(6')-Ie and aph(2'')-Ia, encode a bifunctional 2'-phosphotransferase/6'-acetyltransferase that confers resistance to a broad spectrum of aminoglycosides [13] [14] . Recently, new AMEs genes such as aph(2'')-Ib, aph(2'')-Ic, and aph(2'')-Id have been discovered and they are responsible for high-level gentamicin resistance [11, 14] . Although no single enzyme can inactivate all available aminoglycosides, most VRE strains can produce multiple enzyme types and consequently have the HLAR phenotype [11, 14] .
Additionally, E. faecium have the abilities to produce several virulence factors and to form strong biofi lm structure [4, [15] [16] [17] . The most common virulence determinants are: cytolysin (Cyl), endocarditis antigen (EfaA), enterococcal surface protein (Esp), aggregation substance (As), collagen adhesin (Acm), gelatinase (GelE) and hialuronidase (Hyl) [4, 18] . Cyl is a toxin, encoded by an operon localized on a plasmid or chromosome, which shows haemolytic and bactericidal activity [17] . As, encoded by a plasmid as gene, causes binding to the host epithelium [19] . Acm (acm) and EfaA (efaA) have been identifi ed as the main virulence factors connected with infective endocarditis [4, 15, 20] . Hyl (hyl) degrades hyaluronic acid and, consequently, is associated with tissue damage [21] . Esp (esp), and GelE (gelE), a zinc metalloprotease, are involved in the process of biofi lm formation [4, 18, 22] .
The increasing role of E. faecium, especially VRE and HLAR strains, in nosocomial infections calls for constant monitoring of their susceptibility and virulence. Astonishingly, in the literature there are many conflicting reports about the levels of resistance and virulence among VRE isolates in comparison with susceptible strains (VSE -vancomycin-susceptible Enterococcus) [6, 13, 21, [23] [24] [25] [26] . Moreover, the data about VRE infections in Poland are still very limited [13] . Additionally, it should be noted that many recent studies are based only on phenotypic observations, which have some known limitations and are not fully conclusive [27] [28] [29] . This prompted us to perform a study about the exact comparison of resistance and virulence traits between VRE and VSE clinical isolates with the use of molecular and phenotypic methods. Most of the VRE strains were collected from the haematology (50%) and intensive care units (31.3%), and were isolated mostly from rectal swabs (56%), whereas VSE strains were gathered from intensive care (53%) and surgery (20.7%) units and were isolated from blood (29%) and wound swabs (18%).
Materials and Methods

Strains
Identifi cation and susceptibility testing
The identifi cation and susceptibility testing of study isolates were performed using the VITEK2 system (bioMerieux, France) according to the manufacturer's guidelines using VITEK2 GP and AST-P516 cards, respectively. E. faecalis ATCC 29212 was used as a reference strain. Later, identifi cation was confi rmed by polymerase chain reaction (PCR) with primers targeted to ddl
ß-lactamase production Strains were tested for ß-lactamase production by a chromogenic cephalosporinase method [31] using nitrocefi n discs (OXOID, United Kingdom) as per the manufacturer's instruction.
Hemolysin production
Hemolysin production was evaluated on Columbia blood agar supplemented with 5% sheep blood (OXOID) [32] .
Biofi lm production
Biofi lm formation was determined using two methods: the tube method and the Congo red agar method as described previously [33] [34] . Each experiment was repeated 3 times for each strain. Strains that demonstrated the ability to produce biofi lm by both methods were considered as biofi lm-positive isolates.
DNA extraction
Genomic DNA was extracted from overnight E. faecium cultures using a commercial kit (Genomic Mini Kit, A&A Biotechnology, Poland). 
PCR detection of vancomycin resistance genes, virulence genes, and AME genes
Results
Among 32 VRE strains, 28 were found to be resistant to both vancomycin and teicoplanin; 4 strains were resistant only to vancomycin. Therefore, multiplex PCR for detecting the vancomycin-resistant genes confi rmed that those 28 strains had VanA phenotype and 4 strains the VanB phenotype. Both vanA and vanB genes were not detected in any of the tested isolates.
Resistance and virulence patterns among all VRE and VSE strains are shown in Table 1 AMP IPM CN S TEC VA aac(6')/aph(2'') aph(3') 6 esp efa gelE cLs cLi cA HB 2 AMP IPM CN S TEC VA aac(6')/aph(2'') aph(3') 5 efa gelE cLs cLi cA 1 AMP IPM CN S TEC VA aac(6')/aph(2'') aph(3') 4 esp efa acm hyl HB 4 AMP IPM CN S TEC VA aac(6')/aph(2'') aph(3') esp efa acm hyl H 2 AMP IPM CN S TEC VA aac(6')/aph(2'') aph(3') esp efa acm hyl HB 1 AMP IPM CN S TEC VA aac(6')/aph(2'') aph(3') esp efa acm hyl 1 AMP IPM CN S TEC VA aac(6')/aph(2'') aph(3') 3 esp efa acm HB 2 AMP IPM CN S TEC VA aac(6')/aph(2'') aph(3') esp acm hyl HB 1 AMP IPM CN S TEC VA aac(6')/aph(2'') aph(3') efa acm hyl H 3 5 AMP IPM S TEC VA aac(6')/aph(2'') aph(2')-Ib aph(3') 5 esp efa acm hyl gelE HB 1 AMP IPM CN S VA aac(6')/aph(2'') aph(3') 4
esp efa acm hyl HB 2 AMP IPM S TEC VA aac(6')/aph(2'') aph(3') esp efa acm hyl HB 3 AMP IPM CN TEC VA aac(6')/aph(2'') esp efa acm hyl HB 2 AMP IPM S TEC VA aac(6')/aph(2'') aph(3') 3 esp acm hyl HB 1 AMP IPM S TEC VA aac(6')/aph(2'') aph(3') esp efa hyl 1 AMP IPM S TEC VA aac(6')/aph(2'') aph(3') 2 efa acm HB 1 AMP IPM S TEC VA aac(6')/aph(2'') efa acm HB 1 4 AMP IPM CN VA aac(6')/aph(2'') aph(3') 4 esp efa acm hyl HB 2 AMP IPM TEC VA aac(6')/aph(2'') aph(3') esp efa acm hyl H 1 VSE (n = 34) 4 AMP IPM CN S aac(6')/aph(2'') aph(3') 4 esp efa acm hyl HB 7
AMP IPM CN S aac(6')/aph(2'') aph(3') esp efa acm hyl H 3 AMP IPM CN S aac(6')/aph(2'') aph(3') 3 esp efa acm HB 1 AMP IPM CN S aac(6')/aph(2'') aph(3') esp acm hyl HB 3 AMP IPM CN S aac(6')/aph(2'') aph(3') efa acm hyl HB 1 AMP IPM CN S aac(6')/aph(2'') aph(3') esp efa acm Table 1 shows that VRE isolates were also characterized by a greater variety of resistance and virulence patterns than VSE strains. The exact comparison of antibiotic susceptibility between VRE and VSE isolates revealed that all (100%) strains showed the highest susceptibility to linezolid and tigecycline. VRE isolates were resistant to ß-lactams, whereas, interestingly, two (5.9%) VSE isolates were found to be susceptible to ampicillin and one to imipenem. High-level gentamicin resistance (HLGR) was detected in 2 (5.9%) VSE and 4 (12.5%) VRE strains. High-level streptomycin resistance (HLSR) appeared more frequently in VSE strains (13 (38.2%) and 8 (25%), respectively), while high-level resistance to all aminoglycosides (HLAR) occurred more frequently in VRE strains (16 (47%) and 19 (59.4%)). However, these differences were not statistically signifi cant (p > 0.05).
AMP -ampicillin, IPM -imipenem, CN -gentamicin, S -streptomycin, VA -vancomycin, TEC -teicoplanin, aac(6')/aph(2'') -aac(6')-Ieaph(2'')-Ia, aph(3') -aph(3')-IIIa
This study demonstrates that aac(6')-Ie-aph(2'')-Ia and aph(3')-IIIa genes occur more frequently than others (Table 1 ). The coexistence of these 2 genes was observed in 29 (85.3%) VSE and 29 (90.6%) VRE strains. Interestingly, one VRE strain carried 3 AME genes: aac(6')-Ie-aph(2'')-Ia, aph(3')-IIIa, and aph(2'')-Ib. One VSE isolate and 3 (9.4%) VRE isolates had only aac(6')-Ie-aph(2'')-Ia gene. aph(3')-IIIa gene alone was found in one VSE strain, and the remaining 3 (8.8%) VSE strains did not carry any aminoglycoside-resistant genes. However, no statistically signifi cant differences were found between these two groups of E. faecium (p > 0.05). It should also be noted that newer AME genes such as aph(2'')-Ic, aph(2'')-Id, and ant(4')-Ia were not detected among our study isolates.
Hemolytic activity and biofi lm-forming ability were similar between tested groups; α-hemolysis occurred in 29 (90.6%) VRE and 32 (94.1%) VSE strains; biofi lm production in 24 (75%) VRE and 25 (73.5%) VSE strains. The ability to produce ß-lactamase was not detected in any of the tested isolates. cylA, cylLl, cylLs and gelE genes were only detected in the case of VRE strains; 2 (6.3%) strains carried the Cyl genes and 3 (9.4%) strains -the gelE gene. All (100%) of the VSE and 28 (87.5%) VRE strains had the acm gene. Occurrence of efaA, esp and hyl genes were on similar levels: efaA was detected in 31 (91.2%) VSE and 30 (93.7%) VRE strains, esp in 30 (88.2%) and 26 (81.3%), and hyl in 30 (88.2%) and 25 (78.1%) strains, respectively. These differences were not statistically signifi cant (p > 0.05).
Discussion
The present study focused on comparison of antibiotic resistance and virulence traits between VRE and VSE clinical isolates. Comparison of HLAR between VSE and VRE groups showed that more HLAR and HLGR strains were in the VRE group, and more HLSR strains in the VSE group, although these differences were not statistically signifi cant. This is in accordance with Baldir [39] who also did not fi nd a signifi cant difference in HLGR and HLSR rates among VRE and VSE strains, but did fi nd that the HLAR phenotype occurred signifi cantly more often in VRE isolates. In another study [26] , all three aminoglycoside-resistant phenotypes occurred signifi cantly more frequently among VRE strains. Likewise, Tripathi [40] revealed that resistance to gentamicin prevailed in VRE isolates. Differences between these results may indicate that the resistance to vancomycin does not always correlate with resistance to aminoglycosides, and determination of HLAR among E. faecium strains must always be performed.
We have demonstrated that the bifunctional enzyme coding gene aac(6')-Ie-aph(2'')-Ia and aph(3')-IIIa gene occurred the most frequently, and none of the tested isolates carried newer AME genes such as aph(2'')-Ic, aph(2'')-Id, and ant(4')-Ia. Similar results were reported by other authors [37, [41] [42] [43] . In our study we observed strains with the (6')-Ie-aph(2'')-Ia or aph(3')-IIIa gene but without respected phenotypic resistance towards gentamicin. This may be due to low levels or downregulation of these genes' expression or by inactive gene products.
In our study all of the VRE strains and 94.1% of VSE strains were resistant to ampicillin and imipenem. None of the investigated E. faecium strains showed β-lactamase activity. These results are in agreement with other studies [24] [25] . It should be noted that in this study the majority of tested strains that were resistant to β-lactams also had HLAR phenotype. The occurrence of co-resis-tance between ampicillin and aminoglycosides in VRE isolates is worrisome because it eliminates the synergistic effect between β-lactams and aminoglycosides in the treatment of patients. Moreover, Leavis [44] showed that increasing numbers of β-lactam resistant E. faecium proceeded the growing rates of VRE both in the USA and in Europe. Precisely, high-risk enterococcal clonal complex (CC17), associated with hospital outbreaks of VRE on 5 continents, was strongly correlated with ampicillin resistance. Moreover, ampicillin resistance was followed by resistance to fluoroquinolones and then acquisition of the vanA or vanB gene [44] . Nowadays, Enterococcus spp. isolates resistant to β-lactams, aminoglycosides and glycopeptides are considered as multidrug resistant (MDR), and their increased prevalence and dissemination worldwide cause the necessity of searching for new treatment strategies, including combination therapy [44] [45] [46] .
The presence of cyl and gelE genes among E. faecium strains is rare. Vankerckhoven [47] did not fi nd any cyl and gelE genes with PCR in 271 E. faecium isolates. In our study, both VSE and VRE isolates were shown to be hemolysin producers (>90%), but only 2 of the VRE strains carried the genes of the cyl operon. This may be due to the expression of other hemolysin genes that are yet not known or not so well studied. Interestingly, these cyl-positive strains also had the gelE gene. A small percentage of strains with the gelE gene has also been reported by other researchers [6, 13, 41] but without the coexistence of cyl genes. A recent study performed by Saba Copur [48] showed that more VSE than VRE strains possessed the gelE (25% and 2.2%, respectively) and cyl (50% and 0%) genes, which is not in concordance with our results. On the other hand, Biswas [49] revealed that 44.4% of VRE and 16.4% of VSE isolates contained the gelE gene (p < 0.001).
We reported that the prevalence of esp and hyl genes among tested strains groups was almost equal and, consequently, these differences among isolates were not statistically significant. Similar proportions and lack of signifi cant differences between VSE and VRE isolates were seen by other researchers [6, 21, 48] , but Vankerckhoven [47] and Biswas [49] found that the esp gene was signifi cantly more prevalent among VRE isolates than among VSE strains (77% VRE versus 53% VSE, and 27.8% VRE versus 8.9% VSE, respectively). These contradictory results indicate that the presence of all tested virulence genes cannot be unambiguously correlated with the occurrence of vancomycin resistance among E. faecium strains.
Bacterial ability to form biofi lm is considered to be an important factor in the pathogenesis of enterococcal infection [6, 17, 21] . In our study, over 70% of strains from both VRE and VSE groups were found to produce biofi lm. These results did not coincide with studies by others [6, 15, 21] . Di Rosa [15] found that VRE strains were able to produce biofi lm less frequently (28.8%). Praharaj et al [21] also showed that 13 out of 32 VRE and 70 out of 125 VSE isolates formed biofi lm. However, similarly to our results, there was no signifi cant difference when comparing VRE and VSE groups. Collectively, these data suggest that VRE strains do not produce biofi lm more often than VSE isolates; nevertheless, potential impact of biofi lm forming ability among E. faecium isolates should be taken into account when developing treatment options or infection-control procedures.
VRE was fi rst identifi ed in Europe in 1986, spread rapidly, and is now widespread across Europe [50] . Unfortunately, according to European Centre for Disease Prevention and Control report (2015) , resistance to glycopeptides has significantly increased over the last 4 years, especially in Bulgaria, Croatia, Denmark, Hungary, Ireland, Italy, Slovakia and the United Kingdom. The percentage of VRE varied between 0% in Estonia, Finland, Malta, and Iceland to 45.5% in Ireland. A decrease in the prevalence of the VRE strains, compared to previous years, was reported only in France. In Poland, the fi rst VRE strains were reported in 1996 [51] . Nowadays, the percentage of VRE isolates in Poland has also increased and ranges between 8 and 19%. These varieties and changes in VRE epidemiology are a reflection of differences in antibiotic and infection control policies and remain a major challenge throughout Europe.
In conclusion, both VRE and VSE isolates were well equipped with virulence and resistance genes, although VRE strains were characterized by greater variety and a higher number of these genes. This variety, especially when it occur in combination with phenotypic high-resistance level to antimicrobials, might increase the ability to adhere to artifi cial surfaces, lead to persistence and spreading in hospital environments, and cause more serious nosocomial infections. Moreover, these results suggest that VRE strains slowly acquire and incorporate resistance and virulence traits, due to their ability to survive in hospital environments for a long time. However, statistical analysis revealed no significant differences in the occurrence of tested features between VSE and VRE strains. This can be related to an insuffi cient number of isolates that could have compromised the statistical analysis. Studies with a higher number of heterogeneous VRE and VSE strains should be performed to clarify each type of strain's role in pathogenesis of enterococcal infections. Further studies are also needed on regulation and expression of virulence and resistance genes, how to prevent the spread of MDR enterococcal infections, and on treatment alternatives. Novel pharmacotherapy targeted at specifi c virulence factors such as anti-adhesins may play preventative or even therapeutic role in the elimination of MDR enterococcal infections. Microbiology and Infectious Diseases, Copenhagen, Denmark (25-28.04.2015) .
The results of this work were presented in part at the 25th European Congress of Clinical
